Among respondents that reported using oxytocin for the prevention of PPH (N = 4,908), a majority of them said that they administer oxytocin to clients through intravenous infusion (76.7%) and 48.2 percent of them said they use the intramuscular route to administer oxytocin to clients. The gene discussed is OXT; the disease is pulmonary arterial hypertension.